• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据诊断时肿瘤厚度的不同,黑色素瘤的长期死亡率。

Long-term deaths from melanoma according to tumor thickness at diagnosis.

机构信息

Cancer Council Queensland, Brisbane, Queensland, Australia.

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

出版信息

Int J Cancer. 2020 Sep 1;147(5):1391-1396. doi: 10.1002/ijc.32930. Epub 2020 Feb 28.

DOI:10.1002/ijc.32930
PMID:32067220
Abstract

There is little long-term follow-up information about how the number of melanoma deaths and case fatality vary over time according to the measured thickness of melanoma at diagnosis. This population-based longitudinal cohort study examines patterns and trends in case fatality among 44,531 people in Queensland (Australia) diagnosed with a single invasive melanoma (International Classification of Diseases for Oncology, third revision [ICD-O-3], C44, Morphology 872-879) between 1987 and 2011, including 11,883 diagnosed between 1987 and 1996, with up to 20 years follow-up (to December 2016). The 20-year case fatality increased by thickness, with the percentage of melanoma deaths within 20 years of diagnosis being up to 4.8% for melanomas with measured thickness <0.80 mm, 10.6% for tumors 0.8 to <1.0 mm and generally more than 30% for melanomas measuring 3 mm and more. For melanomas <1.0 mm, most deaths occurred between 5 and 20 years after diagnosis, whereas for thicker melanomas the reverse was true with most deaths occurring within the first 5 years. Five-year case fatality decreased over successive calendar time periods for melanomas <1.0 mm, but not for melanomas ≥1.0 mm. These findings demonstrate that the time course for fatal melanomas varies markedly according to tumor thickness at diagnosis. Improved understanding of the patient factors and characteristics of melanomas, in addition to tumor thickness, which increase the likelihood of progression, is needed to guide clinical diagnosis, communication with patients and ongoing surveillance pathways of patients with potentially fatal lesions.

摘要

关于根据诊断时黑色素瘤的测量厚度,黑色素瘤死亡人数和病死率随时间的变化,几乎没有长期随访信息。这项基于人群的纵向队列研究调查了在昆士兰州(澳大利亚)诊断为单发侵袭性黑色素瘤(国际肿瘤疾病分类学,第三版[ICD-O-3],C44,形态学 872-879)的 44,531 人(1987 年至 2011 年之间)的病死率模式和趋势,包括 1987 年至 1996 年期间诊断出的 11,883 例,随访时间长达 20 年(截至 2016 年 12 月)。20 年病死率随厚度增加而增加,诊断后 20 年内黑色素瘤死亡的百分比在测量厚度<0.80mm 的黑色素瘤中高达 4.8%,在 0.8 至<1.0mm 的肿瘤中为 10.6%,而在测量厚度为 3mm 及以上的黑色素瘤中通常超过 30%。对于<1.0mm 的黑色素瘤,大多数死亡发生在诊断后 5 至 20 年内,而对于较厚的黑色素瘤则相反,大多数死亡发生在最初的 5 年内。<1.0mm 的黑色素瘤的 5 年病死率随连续的日历时间间隔而降低,但≥1.0mm 的黑色素瘤则不然。这些发现表明,致命黑色素瘤的时间过程根据诊断时的肿瘤厚度而有明显差异。需要进一步了解增加进展可能性的患者因素和黑色素瘤特征,除了肿瘤厚度外,还需要进一步了解这些因素,以指导临床诊断,与患者沟通以及对具有潜在致命病变的患者进行持续监测。

相似文献

1
Long-term deaths from melanoma according to tumor thickness at diagnosis.根据诊断时肿瘤厚度的不同,黑色素瘤的长期死亡率。
Int J Cancer. 2020 Sep 1;147(5):1391-1396. doi: 10.1002/ijc.32930. Epub 2020 Feb 28.
2
Clinicopathological factors associated with death from thin (≤ 1·00 mm) melanoma.与薄型(≤1.00毫米)黑色素瘤死亡相关的临床病理因素。
Br J Dermatol. 2020 Apr;182(4):927-931. doi: 10.1111/bjd.18560. Epub 2019 Nov 24.
3
Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia.澳大利亚昆士兰州人群中诊断为薄型黑色素瘤患者的 20 年生存率。
J Clin Oncol. 2012 May 1;30(13):1462-7. doi: 10.1200/JCO.2011.38.8561. Epub 2012 Mar 12.
4
Ten-Year Survival after Multiple Invasive Melanomas Is Worse than after a Single Melanoma: a Population-Based Study.多灶侵袭性黑色素瘤患者的十年生存率低于单灶黑色素瘤患者:一项基于人群的研究。
J Invest Dermatol. 2016 Nov;136(11):2270-2276. doi: 10.1016/j.jid.2016.03.014. Epub 2016 Mar 24.
5
The relationship between melanoma thickness and time to diagnosis in a large population-based study.一项基于大规模人群研究中黑色素瘤厚度与诊断时间的关系。
Arch Dermatol. 2006 Nov;142(11):1422-7. doi: 10.1001/archderm.142.11.1422.
6
Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010.澳大利亚昆士兰州 1982 年至 2010 年首例浸润性或原位性黑色素瘤后继发原发性浸润性黑色素瘤的分布。
JAMA Dermatol. 2014 May;150(5):526-34. doi: 10.1001/jamadermatol.2013.9852.
7
Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002.1982 - 2002年澳大利亚昆士兰州原位和侵袭性黑色素瘤的发病趋势。
Cancer Causes Control. 2006 Feb;17(1):21-7. doi: 10.1007/s10552-005-3637-4.
8
Diagnosis of an additional in situ melanoma does not influence survival for patients with a single invasive melanoma: A registry-based follow-up study.诊断出额外的原位黑色素瘤并不影响单发侵袭性黑色素瘤患者的生存率:一项基于登记处的随访研究。
Australas J Dermatol. 2016 Feb;57(1):57-60. doi: 10.1111/ajd.12429. Epub 2016 Jan 18.
9
The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past.意大利中部地区的黑色素瘤厚度有所下降,但仅限于薄型黑色素瘤,而厚型黑色素瘤仍与以往一样厚。
Melanoma Res. 2010 Oct;20(5):422-6. doi: 10.1097/CMR.0b013e32833d9d36.
10
Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors.薄型(T1)皮肤黑色素瘤患者的长期生存:Breslow 厚度截断值为 0.8mm 可区分高危和低危肿瘤。
Ann Surg Oncol. 2018 Apr;25(4):894-902. doi: 10.1245/s10434-017-6325-1. Epub 2018 Jan 12.

引用本文的文献

1
The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals.血清代谢组可作为一种诊断生物标志物,用于区分黑色素瘤患者与健康个体。
Cell Rep Med. 2025 Aug 19;6(8):102283. doi: 10.1016/j.xcrm.2025.102283. Epub 2025 Aug 11.
2
MTHFD1L is a novel prognostic marker and therapeutic target in cutaneous melanoma.MTHFD1L是皮肤黑色素瘤中一种新的预后标志物和治疗靶点。
Diagn Pathol. 2025 Jul 10;20(1):83. doi: 10.1186/s13000-025-01680-9.
3
Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.
皮肤薄型黑色素瘤患者因黑色素瘤及其他原因导致的死亡风险
JAMA Dermatol. 2025 Feb 1;161(2):167-174. doi: 10.1001/jamadermatol.2024.4900.
4
The Prognostic Value of the 31-Gene Expression Profile Test in Cutaneous Melanoma: A Systematic Review and Meta-Analysis.31基因表达谱检测在皮肤黑色素瘤中的预后价值:一项系统评价与Meta分析
Cancers (Basel). 2024 Nov 4;16(21):3714. doi: 10.3390/cancers16213714.
5
Melatonin/Sericin Wound Healing Patches: Implications for Melanoma Therapy.褪黑素/丝胶伤口愈合贴片:对黑色素瘤治疗的影响。
Int J Mol Sci. 2024 Apr 29;25(9):4858. doi: 10.3390/ijms25094858.
6
Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?黑色素瘤的治疗管理:我们能否利用基因表达谱分析来帮助指导治疗和监测?
Clin Exp Metastasis. 2024 Aug;41(4):439-445. doi: 10.1007/s10585-023-10241-7. Epub 2023 Dec 8.
7
Phosphatase and Tensin Homolog (PTEN) Expression as a Surrogate Biomarker Correlated With the Depth of Invasion in Cutaneous Malignant Melanoma.磷酸酶与张力蛋白同源物(PTEN)表达作为与皮肤恶性黑色素瘤浸润深度相关的替代生物标志物
Cureus. 2023 Sep 15;15(9):e45295. doi: 10.7759/cureus.45295. eCollection 2023 Sep.
8
ACEMID cohort study: protocol of a prospective cohort study using 3D total body photography for melanoma imaging and diagnosis.ACEMID 队列研究:一项使用 3D 全身摄影进行黑色素瘤成像和诊断的前瞻性队列研究方案。
BMJ Open. 2023 Sep 28;13(9):e072788. doi: 10.1136/bmjopen-2023-072788.
9
The Genomic Landscape of Melanoma and Its Therapeutic Implications.黑色素瘤的基因组特征及其治疗意义。
Genes (Basel). 2023 Apr 29;14(5):1021. doi: 10.3390/genes14051021.
10
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.2020 年全球皮肤黑色素瘤负担及 2040 年预测。
JAMA Dermatol. 2022 May 1;158(5):495-503. doi: 10.1001/jamadermatol.2022.0160.